Trial · NCT04341467
Amisulpride Treatment for BPSD in AD Patients
NCT04341467, Not applicable, Unknown, Tianjin Anding Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Amisulpride Treatment for BPSD in AD Patients. Trials, record NCT04341467. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04341467
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Amisulpride Treatment for BPSD in AD Patients
- NCT number
- NCT04341467
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 76 participants, estimated
- Lead sponsor
- Tianjin Anding Hospital
- Conditions
- BPSD, Amisulpride, Olanzapine, Dementia of the Alzheimer Type
- Interventions
- Amisulpride, Olanzapine
- First posted
- 2020-04-10
- Last updated
- 2022-11-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes of neuropsychiatric inventory（NPI）scores | baseline, Week 2,4, and 8 | The change from baseline neuropsychiatric inventory (NPI) items at week 2,4,and 8. Assess the frequency and severity of psychiatric symptoms, including delusions, hallucinations, aggression attacks, depression, anxiety, elevated emotions, indifferent emotions, de-inhibition, agitation, abnormal behaviors, sleep / night behaviors, appetite / eating disorders,the maximum scores is 144.The higher score are considered the psychiatric symptoms more serious. |
| Secondary | Changes of Clinical global impression-Severity of Illness (CGI-SI) score | baseline, Week 2,4, and 8 | The change from baseline Clinical global impression-Severity of Illness (CGI-SI) score. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen The change from baseline Clinical global impression-Severity of Illness (CGI-SI) score. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen |
| Secondary | Changes of Clinical global impression- global improvement (CGI-GI) | baseline, Week 2,4, and 8 | The change from baseline Clinical global impression- global improvement (CGI-GI) items at week 2,4,and 8. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen |
| Secondary | Changes of Mini-Mental State Examination(MMSE) scores. | baseline, Week 2,4, and 8 | The change from baseline Mini-Mental State Examination(MMSE) items at week 2,4,and 8.The content includes time orientation, location orientation, immediate memory of language, attention and calculation, short-term memory, physical naming, language repeating, reading comprehension, speech expression and graphic description. 0 to 30 points, the lower the score, the more severe the cognitive impairment. |
| Secondary | Changes of Caregiver Burden Inventory (CBI) scores | baseline, Week 2,4, and 8 | The change from baseline Caregiver Burden Inventory (CBI) items at week 2,4,and 8.The questionnaire contains 5 dimensions: time-dependent burden, development-restricted burden, physical burden, social burden, and emotional burden. The total score is 96 points. The higher the score, the heavier the burden. |
| Secondary | Treatment Emergent Symptom Scale (TESS) | Week 2,4, and 8 | The scale collection includes 33 items of consciousness disorder, constipation, tremor, etc., to assess the adverse drug reactions and their severity.This table is used to evaluate 33 items of common consciousness disorder, constipation, tremor, etc. based on the adverse drug reactions. Each item is scored according to the severity of the adverse drug reactions. This scale does not need to be evaluated at baseline. |
| Secondary | Rating scale for extrapyramidal side effects (RSESE) | baseline, Week 2,4, and 8 | Assessment of extrapyramidal reactions and their severity at various time points.Assess the severity of 9 aspects of gait, falling arms, shaking shoulders, elbow rigidity, fixed posture or wrist rigidity, leg swings, head and neck movements, tapping between eyebrows, drooling，The total score is 36 points. The higher the score, the more severe extrapyramidal side effects. |
| Secondary | Abnormal Involuntary Movement Scale (AIMS) | baseline, Week 2,4, and 8 | Assesses whether patients have involuntary movements and their severity in the face, limbs, and trunk at various time points.Assess facial movements, body movements, and trunk movements for involuntary movements and severity. A total score of 2 or more is masculine gender. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04341467
GET https://conductscience.org/api/trials/v1/NCT04341467/registered